Company

Passage Bio, Inc.

Passage Bio, based in Pennsylvania, develops AAV-delivered therapies for central nervous system diseases.

About

Established in 2018 and based in Pennsylvania, US, Passage Bio, Inc. is a biotechnology company. It develops adeno-associated virus (AAV)-delivered therapeutics for the treatment of central nervous system diseases. The company is at the Series B stage.

2Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in